Duzodrill

Country of origin: Germany
Pharm-Group: Peripheral vasodilators

Manufacturers: Bik Gulden GmbH (Germany)
International name: Naftidrofuryl
Synonyms: Enelbin
Dosage forms: dragee 50 mg, dragee retard 100 mg, solution for injection 8 mg/ml
Composition: Active substance - naftidrofuryl

Indications for use: Poor circulation in obliterating lesions of the peripheral vessels of the lower extremities (intermittent claudication syndrome, Raynaud's disease), trophic disorders (bedsores, long-term non-healing ulcers, diabetic angiopathy), aseptic necrosis of the femoral head (initial stage), cerebrovascular accidents, cerebral failure with mnestic disorders and hearing loss in old age (with the exception of senile dementia and Alzheimer's disease), idiopathic hearing loss, Meniere's disease, post-traumatic encephalopathy, diseases of the retinal arteries.

Contraindications: Hypersensitivity, acute myocardial infarction, acute hemorrhagic stroke, severe heart failure, arrhythmia, increased bleeding, epilepsy, pregnancy, lactation, childhood.

Side effects: Weakness, headache, sleep disturbances, agitation, decreased blood pressure, orthostatic dizziness and collapse, tachycardia, nausea, epigastric pain, esophagitis, diarrhea, changes in the level of liver enzymes, allergic skin reactions.

Interaction: Increases the severity of the negative cardiotropic effects of beta-blockers and other antiarrhythmic drugs. The solution for injection is pharmaceutically incompatible with calcium ions.

Overdose: Symptoms - confusion, convulsions. Treatment is gastric lavage, administration of activated carbon, monitoring and maintenance of vital functions.

Special instructions: Use with caution if you are prone to vascular collapse, orthostatic dizziness, or increased convulsive readiness. Lack of clinical improvement in elderly patients requires discontinuation of treatment. During use, it is recommended to refrain from smoking and drinking alcohol. Should not be used during work by vehicle drivers and people whose profession involves increased concentration of attention.

Literature:

1. Register of Medicines 2003.
2. Barradell L.B., Brogden R.N. Oral naftidrofuryl//Drugs Aging.- 1996.- N 8.- P. 299-322.
3. Lehert P., Comte S., Gamand S., Brown T.M. Naftidrofuryl in intermittent claudication: a retrospective analysis//J. Cardiovasc. Pharmacol. - 1994. - Vol.23, Suppl. 3. - P. S48-S52.